248
Participants
Start Date
September 30, 2004
Primary Completion Date
November 30, 2006
Study Completion Date
November 30, 2006
becatecarin
Dose: 140 mg/m2 x day Mode of administration: i.v. via central venous catheter Duration of treatment: Days 1 through 5 of a 28 day cycle
5-Fluorouracil Plus Leucovorin
5-Fluorouracil (5-FU) + Leucovorin (LV) Dose: 375 mg /m2/day + 25 mg/m2/day Mode of administration: i.v. via central venous catheter or alternative i.v. administration.Duration of treatment: Days 1 through 5 of a 28 day cycle
New York Medical College, Valhalla
Queens Hospital Center, Jamaica
SUNY Upstate Medical University, Syracuse
CHU - Hospital Jean Minjoz, Besançon
Hospital Clínico San Carlos, Madrid
Hospital 12 de Octubre, Madrid
Charleston Hematology Oncology, PA, Charleston
Winship Cancer Institute, Emory University Hospital, Atlanta
Policlinico Universitario di Udine, Udine
Tampa General Hospital, Tampa
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham
The Sarah Cannon Cancer Center, Nashville
Case Western Reserve University, Cleveland
Gabrail Cancer Center, Canton
Medical Consultants, PC c/o Ball Cancer Center, Muncie
Josephine Ford Cancer Center at Henry Ford Health System, Detroit
West Michigan Cancer Center, Kalamazoo
Oncology Care Center PLLC, Saint Joseph
Hospital Lozano Blesa, Zaragoza
Oncology Associates, Cedar Rapids
University of Wisconsin Comprehensive Cancer Center, Madison
Ospidale Civile di Livorno, Livorno
Cancer Treatment and Research Center, Bismarck
Carle Clinic Association, Urbana
Louisiana Oncology Associates, Lafayette
Technischen Universitat Munchen, Munich
Long Beach VA Medical Center, Long Beach
Hospital Ambroise Pare, Boulogne-Billancourt
Sharp Clinical Oncology Research, San Diego
University of California, Irvine Medical Center, Orange
Pacific Hematology Oncology Associates, San Francisco
Institut Gustave Roussy, Villejuif
Western Washington Oncology, Inc., Lacey
Cancer Research Center named after N.N. Blokhin, RAMS, Moscow
Yale University School of Medicine, New Haven
Tufts - New England Medical Center, Boston
Norris Cotton Cancer Center, Lebanon
Universitair Ziekenhuis Gent, Ghent
Ottawa Regional Cancer Centre, Ottawa
Centre Hospitalier Universite de Montreal, Montreal
Jewish General Hospital, Montreal
Klinikum Grosshadern der Ludwig Maximilians Universitaet, Munich
Orszagos Onkologiai Intezet, Budapest
Centro di Riferimento Oncologico di Aviano, Aviano
Hospital Regional Universitario Carlos Haya, Málaga
Hospital Provincial de Pontevedra, Pontevedra
Leicester Royal Infirmary, Leicester
British Columbia Cancer Agency - Vancouver Centre, Vancouver
London Regional Cancer Centre, London
Centre Oscar Lambret, Lille
Charite Berlin der Humbold Universitat, Berlin
Heinrich-Heine-Universitat-Dusseldorf, Düsseldorf
Allgem. Krankenhaus St. Georg, Hamburg
Medizinische Hochschule Hannover, Hanover
Universitätsklinikum Johannes Gutenberg, Mainz
Universitätsklinikum Tübingen, Tübingen
Universitatsklinikum Ulm, Ulm
Centrum Onkologii - Instytut im. Marii, Warsaw
Hospital Clinic i Provincial (Oncology Department), Barcelona
Lead Sponsor
Helsinn Healthcare SA
INDUSTRY